In order to help you expedite the request process with us, we put together a quick prescription guideline.
Resources
-
March 02, 2020
-
January 21, 2020
5 common questions about the supplement that may be useful for ALS, Parkinson's and Alzheimers.
-
October 30, 2019
New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.
-
October 24, 2019
As a pioneer of a completely new type of global service, we understand that trust, security and credibility are paramount–especially when paying for medicines which are essential and often the only treatment option available. There are an increasing number of scam websites and we ourselves have been the subject of one such scam. In this article we’ll give you tips on how to spot these fakers.
-
September 27, 2019
I’m lucky. It's been 4 years since the first MND symptoms, only my voice has been impacted.
-
September 10, 2019
Two and a half years after his diagnosis, David found a medicine with off-label application for MND.
-
September 02, 2019
Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.
-
August 29, 2019
Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.
-
August 16, 2019
Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.
-
August 15, 2019
Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.
-
August 14, 2019
After 40 years with primary biliary cholangitis, Fiona's mother is still alive thanks to her daughter's dedication and a liver transplant.
-
July 29, 2019
After 3 years of living with ALS, Marc found a new medicine on the other side of the world.
-
July 22, 2019
With tears, laughter and hope, Mark and his family find their own way to cope with ALS.
-
July 22, 2019
Diagnosed with ALS only 6 months ago, Peter went against the current to find more options to treat his disease.
-
MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses.